Description
Alluvi Retatrutide 20mg provides researchers with a lower-dose option for flexible study protocols and dose-escalation research designs. Ideal for initial studies or dose-response investigations.
Key Features:
• Triple agonist (GLP-1, GIP, Glucagon receptors)
• 20mg total dose per pen
• 4 doses of 5mg each
• Once-weekly administration
• Alluvi Healthcare quality assurance
• Includes 12 disposable needles and instruction guide
Research Applications:
The 20mg formulation is particularly valuable for:
• Dose-response studies
• Safety and tolerability assessments
• Initial research protocols
• Comparative studies with other peptides
• Metabolic pathway investigations
Administration Protocol:
Subcutaneous injection only. The lower dose makes this option suitable for early-stage research or when dose titration is required. Store refrigerated at 2°C to 8°C.
Quality Standards:
Alluvi maintains pharmaceutical-grade manufacturing standards. Each batch undergoes comprehensive testing for purity, potency, and sterility.
⚠️ Research Disclaimer:
This product is intended for research purposes only. It is not intended for human consumption or medical use. Always consult with qualified professionals before use.
